Literature DB >> 18398511

Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection.

Christofer Samuelsson1, Jürgen Hausmann, Henning Lauterbach, Michaela Schmidt, Shizuo Akira, Hermann Wagner, Paul Chaplin, Mark Suter, Meredith O'Keeffe, Hubertus Hochrein.   

Abstract

Poxviruses such as the causative agent of smallpox have developed multiple strategies to suppress immune responses, including the suppression of DC activation. Since poxviruses are large DNA viruses, we hypothesized that their detection by DCs may involve the endosomal DNA recognition receptor TLR9. Indeed, we have shown here that DC recognition of ectromelia virus (ECTV), the causative agent of mousepox, completely depended on TLR9. The importance of TLR9 was highlighted by the fact that mice lacking TLR9 showed drastically increased susceptibility to infection with ECTV. In contrast, we found that the strongly attenuated poxvirus modified vaccinia virus Ankara (MVA) activated DCs by both TLR9-dependent and -independent pathways. We therefore tested whether we could use the broader induction of immune responses by MVA to protect mice from a lethal infection with ECTV. Indeed, MVA given at the same time as a lethal dose of ECTV protected mice from death. Importantly, MVA also rescued TLR9-deficient mice if administered 2 full days after an otherwise lethal infection with ECTV. Therefore, these data suggest an essential role for TLR9 in the defense against poxviruses. In addition, postexposure application of MVA may protect against lethal poxvirus infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398511      PMCID: PMC2289795          DOI: 10.1172/JCI33940

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  Poxviruses and immune evasion.

Authors:  Bruce T Seet; J B Johnston; Craig R Brunetti; John W Barrett; Helen Everett; Cheryl Cameron; Joanna Sypula; Steven H Nazarian; Alexandra Lucas; Grant McFadden
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

3.  Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.

Authors:  J Engelmayer; M Larsson; M Subklewe; A Chahroudi; W I Cox; R M Steinman; N Bhardwaj
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

4.  Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

Authors:  Koert J Stittelaar; Geert van Amerongen; Ivanela Kondova; Thijs Kuiken; Rob F van Lavieren; Frank H M Pistoor; Hubert G M Niesters; Gerard van Doornum; Ben A M van der Zeijst; Luis Mateo; Paul J Chaplin; Albert D M E Osterhaus
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Can postexposure vaccination against smallpox succeed?

Authors:  Philip P Mortimer
Journal:  Clin Infect Dis       Date:  2003-02-18       Impact factor: 9.079

6.  Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9.

Authors:  Anne Krug; Gary D Luker; Winfried Barchet; David A Leib; Shizuo Akira; Marco Colonna
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

7.  Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice.

Authors:  Barbara Spies; Hubertus Hochrein; Martin Vabulas; Katharina Huster; Dirk H Busch; Frank Schmitz; Antje Heit; Hermann Wagner
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

8.  Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection.

Authors:  Koichi Tabeta; Philippe Georgel; Edith Janssen; Xin Du; Kasper Hoebe; Karine Crozat; Suzanne Mudd; Louis Shamel; Sosathya Sovath; Jason Goode; Lena Alexopoulou; Richard A Flavell; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

9.  The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense.

Authors:  Mary T Harte; Ismar R Haga; Geraldine Maloney; Pearl Gray; Patrick C Reading; Nathan W Bartlett; Geoffrey L Smith; Andrew Bowie; Luke A J O'Neill
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

10.  Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells.

Authors:  Jennifer Lund; Ayuko Sato; Shizuo Akira; Ruslan Medzhitov; Akiko Iwasaki
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  74 in total

1.  N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Authors:  Meike S Gratz; Yasemin Suezer; Melanie Kremer; Asisa Volz; Monir Majzoub; Kay-Martin Hanschmann; Ulrich Kalinke; Astrid Schwantes; Gerd Sutter
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

3.  A major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC?

Authors:  Stefan Bauer; Barbara Bathke; Henning Lauterbach; Juliane Pätzold; Ronny Kassub; Christian A Luber; Beatrix Schlatter; Svetlana Hamm; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

4.  Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 5.  Recent insights into the role of Toll-like receptors in viral infection.

Authors:  M Carty; A G Bowie
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

6.  Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

7.  Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway.

Authors:  Peihong Dai; Hua Cao; Taha Merghoub; Francesca Avogadri; Weiyi Wang; Tanvi Parikh; Chee-Mun Fang; Paula M Pitha; Katherine A Fitzgerald; Masmudur M Rahman; Grant McFadden; Xiaoyu Hu; Alan N Houghton; Stewart Shuman; Liang Deng
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 8.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

Review 9.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

10.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.